medigraphic.com
Colegio de Medicina Interna de México.

2020, Número 4

<< Anterior Siguiente >>

Med Int Mex 2020; 36 (4)


COVID-19: lo que debemos saber en Colombia

Forero-Saldarriaga S

Idioma: Español
Referencias bibliográficas: 30
Paginas: 543-549
Archivo PDF: 220.11 Kb.


RESUMEN

El nuevo coronavirus 2 del síndrome respiratorio agudo severo (SARS-CoV-2) es la causa de la propagación rápida de una enfermedad que afecta a miles de personas en todo el mundo. El 11 de marzo de 2020, la Organización Mundial de la Salud declaró el brote de COVID-19 como una pandemia. El virus se ha identificado como la causa de un brote de neumonía de causa desconocida en la ciudad de Wuhan, China, en diciembre de 2019. La manifestación clínica es la de una infección respiratoria con gravedad de los síntomas que va desde una enfermedad leve similar al resfriado común hasta una neumonía viral grave que provoca síndrome de dificultad respiratoria aguda potencialmente mortal. No hay tratamiento específico disponible que se haya probado clínicamente, diferente al tratamiento de soporte.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Chen Y, Liu Q, Guo D. Emerging coronaviruses: Genome structure, replication, and pathogenesis. J Med Virol [Internet] 2020; 92(4): 418-23. https://doi.org/10.1002/ jmv.25681

  2. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in wuhan, china, of novel coronavirus– infected pneumonia. N Engl J Med [Internet] 2020. https://doi.org/10.1056/NEJMoa2001316

  3. WHO Director-General’s remarks at the media briefing on 2019-nCoV on 11 February 2020. https://www.who.int/ dg/speeches/detail/who-director-general-s-remarks-atthe- media-briefing-on-2019-ncov-on-11-february-2020

  4. Novel Coronavirus -COVID-2019- geographic distribution in the Americas [Internet]. https://who.maps.arcgis. com/apps/webappviewer/index.html?id=2203b04c3a5f 486685a15482a0d97a87&extent=-20656313.6818%2C- 3596894.4332%2C1611932.8945%2C7390469.7606%2C 102100&site=paho

  5. CDC. International Locations with Confirmed COVID-19 Cases [Internet]. Centers for Disease Control and Prevention. 2020. https://www.cdc.gov/coronavirus/2019-ncov/ cases-updates/world-map.html

  6. Johns Hopkins Coronavirus Resource Center [Internet]. Johns Hopkins Coronavirus Resource Center. https:// coronavirus.jhu.edu/

  7. WHO Director-General’s opening remarks at the media briefing on COVID-19 - 24 February 2020. https://www. who.int/dg/speeches/detail/who-director-generals- opening-remarks-at-the-media-briefing-on-covid- 19---24-february-2020

  8. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet [Internet]. 2020. https://doi.org/10.1016/S0140- 6736(20)30251-8

  9. van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med [Internet]. 2020. https://doi.org/10.1056/ NEJMc2004973

  10. Bai Y, Yao L, Wei T, Tian F, Jin D-Y, Chen L, et al. Presumed asymptomatic carrier transmission of COVID-19. JAMA [Internet]. 2020. https://doi:10.1001/jama.2020.2565

  11. Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature [Internet] 2020; 579(7798): 270-3. Disponible en: https://doi.org/10.1038/s41586- 020-2012-7

  12. Perlman S, Netland J. Coronaviruses post-SARS: update on replication and pathogenesis. Nat Rev Microbiol [Internet]. 2020; 7(6): 439-50. https://doi.org/10.1038/nrmicro2147

  13. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet [Internet] 2020; 395(10223): 497-506. https://doi.org/10.1016/S0140-6736(20)30183-5

  14. Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA 2020. https://doi:10.1001/jama.2020.4683

  15. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395(10223): 507-13. https://doi. org/10.1016/S0140-6736(20)30211-7

  16. Fan E, Brodie D, Slutsky AS. Acute respiratory distress syndrome: advances in diagnosis and treatment. JAMA 2020; 319(7): 698-710. https://doi:10.1001/jama.2017.21907

  17. Aldana N, Arias L, Bayona J, Carrillo J, Pinzón B, et al. Recomendaciones de la Asociación Colombiana de Radiología para el transporte, realización de estudios, aislamiento de equipos, medidas de seguridad del personal e interpretación de imágenes diagnósticas durante la pandemia por el COVID-19. 2020. https://mcusercontent. com/4f6e5a780e91bad256d5ee2de/files/837768ba-4d4b- 4039-8b2f-fec3ea614b82/Recomendaciones_Generales_ ACR_COVID_19_marzo_23.01.pdf

  18. UPDATED BSTI COVID-19 Guidance for the Reporting Radiologist | The British Society of Thoracic Imaging [Internet]. 2020. https://www.bsti.org.uk/media/resources/files/ BSTI_COVID-19_Radiology_Guidance_version_2_16.03.20

  19. Trujillo CHS. Consenso colombiano de atención, diagnóstico y manejo de la infección por SARS-COV-2/COVID 19 en establecimientos de atención de la salud. Recomendaciones basadas en consenso de expertos e informadas en la evidencia. Infectio [Internet] 2020; 24(3): 1-102. http:// dx.doi.org/10.22354/in.v24i3.851

  20. Alhazzani W et al. Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19). Intensive Care Med 2020. https:// www.sccm.org/getattachment/Disaster/SSC-COVID19- Critical-Care-Guidelines.pdf

  21. Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, et al. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA [Internet] 2020. https://doi:10.1001/jama.2020.3786

  22. Xie X, Zhong Z, Zhao W, Zheng C, Wang F, Liu J. Chest CT for typical 2019-nCoV pneumonia: Relationship to negative RT-PCR testing. Radiology [Internet] 2020; 200343. https:// doi:10.1148/radiol.2020200343

  23. COVID-19 Rapid Test [Internet]. 2020. https://www.biopanda. co.uk/php/products/rapid/infectious_diseases/ covid19.php

  24. Coronavirus, COVID-19, SARS [Internet]. Sanford Web Edition. https://webedition.sanfordguide.com/en/sanfordguide- online/disease-clinical-condition/coronavirus

  25. Colson P, Rolain J-M, Lagier J-C, Brouqui P, Raoult D. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents 2020; 105932. https://doi.org/10.1016/j.ijantimicag.2020.105932

  26. Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis https://doi:10.1093/cid/ciaa237/5801998

  27. Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. International J Antimicrob Agents 2020; 105949. https://doi.org/10.1016/j.ijantimicag.2020.105949

  28. Mehra MR, Desai SS, Ruschitzka F, Patel AN. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet 2020; S0140673620311806. https://doi. org/10.1016/S0140-6736(20)31180-6

  29. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 2020. https://doi.org/10.1056/ NEJMoa2001282

  30. Martinez MA. Compounds with therapeutic potential against novel respiratory 2019 coronavirus. Antimicrob Agents Chemother 2020. https://DOI:10.1128/AAC.00399-20




2020     |     www.medigraphic.com